SHR-A1811
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Conditions
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Trial Timeline
Jun 4, 2024 → Sep 1, 2025
NCT ID
NCT06413745About SHR-A1811
SHR-A1811 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for HER2 Expression / Amplification in Patients With Biliary Tract Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06413745. Target conditions include HER2 Expression / Amplification in Patients With Biliary Tract Cancer.
What happened to similar drugs?
2 of 20 similar drugs in HER2 Expression / Amplification in Patients With Biliary Tract Cancer were approved
Approved (2) Terminated (1) Active (17)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06413745 | Phase 2 | Recruiting |
| NCT04818333 | Phase 1/2 | Active |
| NCT04513223 | Phase 1 | Completed |
| NCT04446260 | Phase 1 | Completed |
Competing Products
20 competing products in HER2 Expression / Amplification in Patients With Biliary Tract Cancer